BLOOD 2022: Daratumumab Significantly Prolongs Progression-Free Survival for Patients With Relapsed/Refractory Multiple Myeloma
Daratumumab plus bortezomib and dexamethasone offers hope for multiple myeloma patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.